Zheng Quan Shi Bao·2025-04-20 15:09Core Viewpoint - The Shenzhen Stock Exchange held its first collective performance briefing for listed companies in 2024, focusing on the theme "New Growth for Enterprises: Private Enterprises Competing in the Middle Stream," showcasing the latest developments of private enterprises and addressing investor concerns regarding technological innovation, tariff challenges, internationalization, and development strategies [1]. Group 1: Technological Innovation - Innovation is identified as the core driving force for the development of the private economy, with Shenzhen's private listed companies making significant investments in R&D, technology innovation, and patent accumulation [3]. - Jianfan Bio focuses on the R&D, production, and sales of biomedical materials and high-tech medical devices, particularly excelling in blood purification technology, and plans to enhance production management and diversify its product line [3]. - ZhiJian Electronics, a leader in consumer lithium-ion batteries, is committed to a forward-looking R&D strategy and aims to enhance its core competitive advantages while exploring market growth opportunities [3]. - Wanfu Bio sees digital pathology as a significant transformation opportunity and is developing comprehensive digital pathology solutions to reduce doctors' workloads [4]. - Xinlitai is exploring AI applications in drug discovery and clinical research to improve innovation efficiency and plans to deepen AI's role in drug design and data mining [4]. Group 2: Tariff Challenges - Companies are closely monitoring international trade policies and are implementing measures such as increasing domestic sales and developing new overseas markets to mitigate the impact of high tariffs imposed by the U.S. [6]. - Zongshen Power reported that its domestic sales accounted for 51.99% of total revenue in 2024, slightly higher than export business, and has taken proactive measures to address tariff risks [6]. - Yunjigroup highlighted that its supply chain has a high localization rate, effectively mitigating tariff fluctuations, and is capitalizing on new overseas projects due to the ongoing high prosperity cycle in the mining industry [7]. - Jianfan Bio is expanding into new markets while increasing its overseas business share, particularly in heavy liver disease and critical illness applications [7]. - Wanfu Bio has over 20 years of experience in international markets and continues to innovate to maintain growth in its international business despite tariff challenges [7]. Group 3: Development Trends - Shenzhen's private listed companies demonstrate resilience and vitality, with a significant number of companies contributing to economic development and technological innovation [9]. - As of March 2025, there are 2,181 private listed companies in Shenzhen, accounting for 76% of the total, with a combined market value of 22.65 trillion yuan, representing 69% of the total market value [9]. - In 2023, 582 private enterprises disclosed their annual reports, achieving a total revenue of 6.25 trillion yuan, a year-on-year increase of 6.62%, and a net profit of 419.9 billion yuan, a growth of approximately 1% [9]. - Jianfan Bio is investing in high-value resin and medical device projects, aiming to enhance market share and secure product supply [10]. - Xinlitai is transitioning from generic to innovative drugs, with increasing revenue contributions from new patented products [11].